BOSTON, MA, February 4, 2007 — PAREXEL International Corporation, (Nasdaq: PRXL) one of the world’s largest biopharmaceutical outsourcing companies, today announced that it now provides Biopharmaceutical Development Consulting Services in support of emerging, virtual, and biotechnology firms. Through this new service offering, PAREXEL assists clients in formulating detailed strategies to optimize critical early-stage and advanced-stage product development. In addition, by providing senior-level strategic perspective, this new service more effectively leverages PAREXEL’s global expertise, experience and resources while maximizing value and efficiencies for full development program lifecycles.
Clients may improve the return on their nonclinical and clinical development investments by relying on PAREXEL’s global portfolio of services, capabilities and expertise ranging from early drug development to clinical/regulatory strategy and to post-marketing support. PAREXEL’s Biopharmaceutical Development Consulting team consists of worldwide regulatory, medical and scientific experts who understand client technology, regulatory requirements, clinical trial design and analysis and can create innovative strategic solutions to regulatory, clinical and non-clinical development challenges.
During the past twenty years, PAREXEL has accumulated broad experiences with international regulatory agencies on behalf of its biopharmaceutical clients, and has assisted them in achieving time and cost-effective pathways to market through the design and performance of Phase I/II studies in Europe and in the United States. PAREXEL’s five clinical pharmacology research units located in Europe, South Africa and the United States offer the capability to generate crucial pharmacodynamic and pharmacokinetic data to support the design of key Phase II and III clinical trials. These services are often supplemented by the formulation of a sound clinical and regulatory strategic plan, essential in securing investment capital as well as eventual regulatory approval for marketing, and in conducting sophisticated evaluations of competitive or synergistic technologies for in-licensing opportunities. PAREXEL’s Biotech Development Consulting Services group includes scientific, manufacturing and Chemistry Manufacturing and Control (CMC), regulatory, and medical expertise that adds a broad and in-depth perspective on the complex issues surrounding early-stage biopharmaceutical development.
“We remain dedicated to enhancing the value of biopharmaceutical projects and reducing drug development time,” said Josef H. von Rickenbach, Chairman and Chief Executive Officer. “PAREXEL provides biopharmaceutical development consulting services because we recognize the key business, regulatory, clinical, and scientific issues of importance to our clients and we therefore aim to address their key drug development issues more effectively”.
This release contains "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained here in that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends" and "appears", and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-Q for the period ended September 30, 2001, as filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company disclaims any duty to update any of the forward-looking statements contained in this press release.